Prognostic significance of Versican expression in gastric adenocarcinoma

Oncogenesis

Volumn 4, Issue 11, 2015, Pages

  Shen, X H ^a,b,c   Lin, W R ^a,c   Xu, M D ^a,c   Qi, P ^a,c   Dong, L ^a,c   Zhang, Q Y ^a,c   Ni, S J ^a,c   Weng, W W ^a,c   Tan, C ^a,c   Huang, D ^a,c   Ma, Y Q ^d   Zhang, W ^d   Sheng, W Q ^a,c   Wang, Y Q ^e   Du, X ^a,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b Clinical Pathology Diagnosis Center of Ningbo   (China)

^c FUDAN UNIVERSITY   (China)

^d XINJIANG MEDICAL UNIVERSITY   (China)

^e OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VERSICAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; TUMOR INVASION; TUMOR VOLUME;

EID: 84989348647     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.36     Document Type: Article

References (31)

1. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477-490.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
3. Zigrino P, Loffek S, Mauch C. Tumor-stroma interactions: Their role in the control of tumor cell invasion. Biochimie 2005; 87: 321-328.
4. Ricciardelli C, Rodgers RJ. Extracellular matrix of ovarian tumors. Semin Reprod Med 2006; 24: 270-282.
5. Iozzo RV. Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-652.
6. Dours-Zimmermann MT, Zimmermann DR. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 1994; 269: 32992-32998.
7. Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y. Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep 2010; 23: 917-925.
8. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009; 28: 233-245.
9. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999; 5: 1041-1056.
10. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S et al. Versican overexpression in human breast cancer lesions: Known and new isoforms for stromal tumor targeting. Int J Cancer 2010; 126: 640-650.
11. Pirinen R, Leinonen T, Bohm J, Johansson R, Ropponen K, Kumpulainen E et al. Versican in nonsmall cell lung cancer: Relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 2005; 36: 44-50.
12. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002; 160: 549-557.
13. Pukkila MJ, Kosunen AS, Virtaniemi JA, Kumpulainen EJ, Johansson RT, Kellokoski JK et al. Versican expression in pharyngeal squamous cell carcinoma: An immunohistochemical study. J Clin Pathol 2004; 57: 735-739.
14. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ et al. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 2010; 119: 114-120.
15. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Nakamura K et al. Versican expression in human cervical cancer. Eur J Cancer 2007; 43: 1460-1466.
16. Stylianou M, Skandalis SS, Papadas TA, Mastronikolis NS, Theocharis DA, Papageorgakopoulou N et al. Stage-related decorin and versican expression in human laryngeal cancer. Anticancer Res 2008; 28: 245-251.
17. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, Walinski H et al. Versican: Signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006; 84: 77-92.
18. Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F et al. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: A study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Breast Cancer Res 2012; 14: R145.
19. Gorter A, Zijlmans HJ, van Gent H, Trimbos JB, Fleuren GJ, Jordanova ES. Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Mod Pathol 2010; 23: 1605-1615.
20. Pukkila M, Kosunen A, Ropponen K, Virtaniemi J, Kellokoski J, Kumpulainen E et al. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J Clin Pathol 2007; 60: 267-272.
21. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003; 199: 479-487.
22. Ju H, Lim B, Kim M, Noh SM, Han DS, Yu HJ et al. Genetic variants A1826H and D2937Y in GAG-beta domain of versican influence susceptibility to intestinal-Type gastric cancer. J Cancer Res Clin Oncol 2010; 136: 195-201.
23. Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, Lebaron RG, Horsfall DJ. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 2001; 61: 926-930.
24. Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U, Hau P. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007; 96: 1560-1568.
25. Kamitani S, Yamauchi Y, Kawasaki S, Takami K, Takizawa H, Nagase T et al. Simultaneous stimulation with TGF-beta1 and TNF-Alpha induces epithelial mesenchymal transition in bronchial epithelial cells. Int Arch Allergy Immunol 2011; 155: 119-128.
26. Mukaratirwa S, Koninkx JF, Gruys E, Nederbragt H. Mutual paracrine effects of colorectal tumour cells and stromal cells: Modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture. Int J Exp Pathol 2005; 86: 219-229.
27. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC. Dev Biol 2002; 2: 8.
28. Zhang Z, Zhang J, Miao L, Liu K, Yang S, Pan C et al. Interleukin-11 promotes the progress of gastric carcinoma via abnormally expressed versican. Int J Biol Sci 2012; 8: 383-393.
29. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-2516.
30. Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV. Both beta-Actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. Prostate 2008; 68: 1555-1560.
31. Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD et al. Quality control of immunohistochemical evaluation of tumour-Associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 1998; 34: 1334-1340.